Published in J Am Soc Nephrol on January 01, 1992
A novel approach to bilateral hand-assisted laparoscopic nephrectomy for autosomal dominant polycystic kidney disease. Surg Endosc (2006) 0.90
Evaluation and management of pain in autosomal dominant polycystic kidney disease. Adv Chronic Kidney Dis (2010) 0.86
Ablation of symptomatic cysts using absolute ethanol in 11 patients with autosomal-dominant polycystic kidney disease. Korean J Radiol (2004) 0.83
Novel treatments of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol (2014) 0.83
A stepwise approach for effective management of chronic pain in autosomal-dominant polycystic kidney disease. Nephrol Dial Transplant (2014) 0.82
Renal pain in polycystic kidney disease: when the hurt won't stop. J Am Soc Nephrol (1992) 0.81
Unravelling the pathogenesis of cystic kidney diseases. Arch Dis Child (1995) 0.78
Transcatheter arterial embolization using ethanol in a dialysis patient for contracting enlarged polycystic kidneys. Korean J Radiol (2010) 0.77
Cyst ablation using a mixture of N-butyl cyanoacrylate and iodized oil in patients with autosomal dominant polycystic kidney disease: the long-term results. Korean J Radiol (2009) 0.76
Surgical cyst decortication in autosomal dominant polycystic kidney disease. J Endourol (2013) 0.76
Bilateral hand-assisted laparoscopic nephrectomy in adult polycystic kidney disease patients: a UK centre experience. J Med Life (2012) 0.75
Suitability of Patients with Autosomal Dominant Polycystic Kidney Disease for Renal Transcatheter Arterial Embolization. J Am Soc Nephrol (2015) 0.75
Which Stage of ADPKD Is More Appropriate for Decortication? A Retrospective Study of 137 Patients from a Single Clinic. PLoS One (2015) 0.75
Nephrology, dialysis and transplantation. Postgrad Med J (1993) 0.75
Updated data on proximal femur bone mineral levels of US adults. Osteoporos Int (1998) 7.14
Prevalence of low femoral bone density in older U.S. adults from NHANES III. J Bone Miner Res (1997) 5.69
Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med (1990) 5.49
Matched comparison of radical nephrectomy vs nephron-sparing surgery in patients with unilateral renal cell carcinoma and a normal contralateral kidney. Mayo Clin Proc (2000) 4.45
Treatment of postmenopausal osteoporosis with transdermal estrogen. Ann Intern Med (1992) 4.19
Differential changes in bone mineral density of the appendicular and axial skeleton with aging: relationship to spinal osteoporosis. J Clin Invest (1981) 3.60
Structural trends in the aging femoral neck and proximal shaft: analysis of the Third National Health and Nutrition Examination Survey dual-energy X-ray absorptiometry data. J Bone Miner Res (2000) 3.36
Which cyclosporin formulation? Lancet (1996) 3.34
Consensus statement on the live organ donor. JAMA (2000) 3.29
Epidemiology of vertebral fractures in women. Am J Epidemiol (1989) 3.27
Changes in bone mineral density of the proximal femur and spine with aging. Differences between the postmenopausal and senile osteoporosis syndromes. J Clin Invest (1982) 2.92
Identification and characterization of polycystin-2, the PKD2 gene product. J Biol Chem (1999) 2.74
Long-term fracture prediction by bone mineral assessed at different skeletal sites. J Bone Miner Res (1993) 2.59
Osteoporosis and the risk of hip fracture. Am J Epidemiol (1986) 2.35
Analgesics and the kidney: summary and recommendations to the Scientific Advisory Board of the National Kidney Foundation from an Ad Hoc Committee of the National Kidney Foundation. Am J Kidney Dis (1996) 2.30
Sodium ferric gluconate complex in sucrose is safe and effective in hemodialysis patients: North American Clinical Trial. Am J Kidney Dis (1999) 2.24
Synergistic effects of cyclosporine and rapamycin in a chronic nephrotoxicity model. Transplantation (1996) 2.24
Epidemiology of adult polycystic kidney disease, Olmsted County, Minnesota: 1935-1980. Am J Kidney Dis (1983) 2.22
Contralateral adrenal metastasis of renal cell carcinoma: treatment, outcome and a review. BJU Int (2003) 2.17
Defining prostate specific antigen progression after radical prostatectomy: what is the most appropriate cut point? J Urol (2001) 2.15
Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases. J Urol (1998) 2.14
Prevalence of low femoral bone density in older U.S. women from NHANES III. J Bone Miner Res (1995) 2.12
Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy. J Urol (1996) 2.04
Surgical treatment of renal cancer with vena cava extension. Br J Urol (1987) 2.04
Hepatic cyst infection in autosomal dominant polycystic kidney disease. Mayo Clin Proc (1990) 2.02
Rates of bone loss in the appendicular and axial skeletons of women. Evidence of substantial vertebral bone loss before menopause. J Clin Invest (1986) 2.01
PSA doubling time as a predictor of clinical progression after biochemical failure following radical prostatectomy for prostate cancer. Mayo Clin Proc (2001) 1.91
Relative contributions of aging and estrogen deficiency to postmenopausal bone loss. N Engl J Med (1984) 1.90
Classification of vertebral fractures. J Bone Miner Res (1991) 1.89
Long-term hazard of progression after radical prostatectomy for clinically localized prostate cancer: continued risk of biochemical failure after 5 years. J Urol (2000) 1.89
The influence of dosage regimen on experimental gentamicin nephrotoxicity: dissociation of peak serum levels from renal failure. J Infect Dis (1979) 1.83
Assessment of body composition with use of dual-energy x-ray absorptiometry: evaluation and comparison with other methods. Mayo Clin Proc (1993) 1.77
Use of Gleason score, prostate specific antigen, seminal vesicle and margin status to predict biochemical failure after radical prostatectomy. J Urol (2001) 1.72
Idiopathic membranous nephropathy: the natural history of untreated patients. Kidney Int (1988) 1.72
Proximal femur bone mineral levels of US adults. Osteoporos Int (1995) 1.69
Increase in serum bone gamma-carboxyglutamic acid protein with aging in women. Implications for the mechanism of age-related bone loss. J Clin Invest (1983) 1.69
Nephrotoxicity of immunosuppressive drugs: long-term consequences and challenges for the future. Am J Kidney Dis (2000) 1.68
Effect of season on physical activity score, back extensor muscle strength, and lumbar bone mineral density. J Bone Miner Res (1990) 1.66
Cystic fibrosis and the phenotypic expression of autosomal dominant polycystic kidney disease. Am J Kidney Dis (1998) 1.64
Diagnosis of osteoporosis: usefulness of photon absorptiometry at the radius. J Nucl Med (1977) 1.63
Somatic mutation in individual liver cysts supports a two-hit model of cystogenesis in autosomal dominant polycystic kidney disease. Mol Cell (1998) 1.61
Renal oncocytoma: multifocality, bilateralism, metachronous tumor development and coexistent renal cell carcinoma. J Urol (1999) 1.61
A preliminary placebo-controlled crossover trial of fludrocortisone for chronic fatigue syndrome. Arch Intern Med (1998) 1.60
Morphine and phenytoin binding to plasma proteins in renal and hepatic failure. Clin Pharmacol Ther (1975) 1.59
Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer (2001) 1.58
Correlation of back extensor strength with thoracic kyphosis and lumbar lordosis in estrogen-deficient women. Am J Phys Med Rehabil (1996) 1.58
Urachal cancer: role of conservative surgery. Urology (1993) 1.57
Polyaspartic acid prevents experimental aminoglycoside nephrotoxicity. J Infect Dis (1989) 1.57
The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease. Kidney Int (2001) 1.56
Secondary and tertiary structure modeling reveals effects of novel mutations in polycystic liver disease genes PRKCSH and SEC63. Clin Genet (2010) 1.55
Impact of endourology on diagnosis and management of upper urinary tract urothelial cancer. J Urol (1989) 1.55
The incidence of multicentricity in renal cell carcinoma. J Urol (1991) 1.53
Evaluation of four maternal smoking questions. Public Health Rep (1999) 1.52
Vascular expression of polycystin. J Am Soc Nephrol (1997) 1.51
Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer. Urology (1993) 1.50
Anatomic site-specific positive margins in organ-confined prostate cancer and its impact on outcome after radical prostatectomy. Urology (1997) 1.50
Differential effects of endocrine dysfunction on the axial and the appendicular skeleton. J Clin Invest (1982) 1.48
Asymmetric cortical degenerative syndromes: clinical and radiologic correlations. Neurology (1992) 1.47
Disease outcome in patients with low stage renal cell carcinoma treated with nephron sparing or radical surgery. J Urol (1996) 1.47
Renal manifestations of sarcoidosis. Arch Intern Med (1981) 1.47
Long-term outcome in patients with pTxN+ adenocarcinoma of prostate treated with radical prostatectomy and early androgen ablation. J Urol (1998) 1.46
Stronger back muscles reduce the incidence of vertebral fractures: a prospective 10 year follow-up of postmenopausal women. Bone (2002) 1.46
An evaluation of forearm bone mineral measurement with dual-energy X-ray absorptiometry. J Nucl Med (1991) 1.46
Silicone breast implants: immunotoxic and epidemiologic issues. Life Sci (1995) 1.46
Prostate specific antigen values after radical retropubic prostatectomy for adenocarcinoma of the prostate: impact of adjuvant treatment (hormonal and radiation) J Urol (1991) 1.46
Determinants of renal volume in autosomal-dominant polycystic kidney disease. Kidney Int (2007) 1.44
Bone densitometry and clinical decision-making in osteoporosis. Ann Intern Med (1988) 1.43
The percent of cores positive for cancer in prostate needle biopsy specimens is strongly predictive of tumor stage and volume at radical prostatectomy. J Urol (2000) 1.42
Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice. Mayo Clin Proc (1998) 1.42
Measurement of bone mineral content in human vertebrae and hip by dual photon absorptiometry. Radiology (1980) 1.42
Potency-sparing radical retropubic prostatectomy: a simplified anatomical approach. J Urol (1995) 1.41
Acute renal failure from ticrynafen. N Engl J Med (1979) 1.40
Primary chemotherapy for clinical stage II nonseminomatous germ cell testicular tumors: selection criteria and long-term results. Mayo Clin Proc (1995) 1.40
Pitfalls of "bench surgery" and autotransplantation for renal cell carcinoma. Mayo Clin Proc (1992) 1.39
A mouse model of autosomal recessive polycystic kidney disease with biliary duct and proximal tubule dilatation. Kidney Int (2007) 1.38
[The diagnosis of the osteoporosis risk. New developments and the state of the art 1994]. Dtsch Med Wochenschr (1994) 1.38
Posaconazole pharmacokinetics, safety, and tolerability in subjects with varying degrees of chronic renal disease. J Clin Pharmacol (2005) 1.37
Liver resection and cyst fenestration in the treatment of severe polycystic liver disease. Gastroenterology (1995) 1.36
The influence of tobramycin dosage regimens on nephrotoxicity, ototoxicity, and antibacterial efficacy in a rat model of subcutaneous abscess. J Infect Dis (1988) 1.36
Action and toxicity of cyclosporine. Annu Rev Med (1986) 1.35
Validation of Partin tables for predicting pathological stage of clinically localized prostate cancer. J Urol (2000) 1.33
Paraganglioma of the urinary bladder: can biologic potential be predicted? Cancer (2000) 1.33
Quantification and longitudinal trends of kidney, renal cyst, and renal parenchyma volumes in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (2000) 1.32
Squamous papilloma of the urinary tract is unrelated to condyloma acuminata. Cancer (2000) 1.32
Nephrotoxicity of immunosuppressive drugs: new insight and preventive strategies. Curr Opin Crit Care (2001) 1.32
Biochemical changes during development of mouse mammary tissue in organ culture. J Endocrinol (1970) 1.31
The progression of vesicoureteral reflux nephropathy. Ann Intern Med (1980) 1.31
Effect of cations on the consideration of hen erythrocyte nuclei and its relation to gene activation. Exp Cell Res (1972) 1.29
Primary grade 1 transitional cell carcinoma of the renal pelvis and ureter. J Urol (1980) 1.29
Interpretation of serum tri-iodothyronine levels measured by the sterling technic. N Engl J Med (1971) 1.28
Imaging-guided radiofrequency ablation of solid renal tumors. AJR Am J Roentgenol (2003) 1.27
Renal cell carcinoma metastatic to the pancreas: clinical and radiological features. Mayo Clin Proc (2000) 1.26
Stimulation by insulin of the formation of ribonucleic acid and protein by mammary tissues in vitro. Biochem J (1966) 1.26
Outcome of isolated renal cell carcinoma fossa recurrence after nephrectomy. J Urol (2000) 1.26
Intestinal perforation due to fecal impaction after renal transplantation. J Urol (1976) 1.25
Renal cell carcinoma in autosomal dominant polycystic kidney disease. J Am Soc Nephrol (1994) 1.25
Lead nephropathy. Kidney Int (1985) 1.24
Identification of a locus for autosomal dominant polycystic liver disease, on chromosome 19p13.2-13.1. Am J Hum Genet (2000) 1.24